skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: SU-F-T-327: Total Body Irradiation In-Vivo Dose Measurements Using Optically Stimulated Luminescence (OSL) NanoDots and Farmer Type Ion Chamber

Abstract

Purpose: This study was performed to analyze the agreement between optically stimulated luminescence (OSL) nanoDots measured doses and 0.6 cc Farmer type ionization chamber measured doses during total body irradiation (TBI). Methods: In-vivo dose measurements using OSL nanoDots and Farmer chamber were done in a total of twelve patients who received TBI at our center by bilateral parallel-opposed beams technique. In this technique, the patient is kept inside the TBI box which is filled with rice bags and irradiated using two bilateral parallel opposed beams of 40×40 cm{sup 2} size with 45° collimator rotation at an SSD of 333.5 cm in an Elekta Synergy linear accelerator. All patients received a dose of 2 Gy in single fraction as conditioning regimen. The beams were equally weighted at the midplane of the box. The nanoDots were placed over forehead, right and left neck, right and left lung, umbilicus, right and left abdomen, medial part of thigh, knee and toe. A 0.6 cc Farmer chamber was placed in between the thighs of the patient. Measured doses are reported along with the statistical comparisons using paired sample t-test. Results: For the above sites the mean doses were 212.2±21.1, 218.2±7.6, 218.7±9.3, 215.6±9.5, 217.5±11.5, 214.5±7.7, 218.3±6.8,more » 221.5±15, 229.1±11.0, 220.5±7.7 and 223.3±5.1 cGy respectively. For all OSL measurements the mean dose was 218.6±11.8 cGy. Farmer chamber measurements yielded a mean dose of 208.8±15.6 cGy. Statistical analysis revealed that there was no significant difference between OSL measured doses in forehead, right and left neck, right and left lung, umbilicus, right and left abdomen and toe and Farmer chamber measured doses (0.72≤p≤0.06). However the mean OSL doses at thigh and knee were statistically different (p<0.05) from the Farmer chamber measurements. Conclusion: OSL measurements were found to be in agreement with Farmer type ionization chamber measurements in in-vivo dosimetry of TBI.« less

Authors:
; ; ; ; ; ; ; ; ; ;  [1]
  1. Fortis Memorial Research Institute, Gurgaon, Haryana (India)
Publication Date:
OSTI Identifier:
22648933
Resource Type:
Journal Article
Resource Relation:
Journal Name: Medical Physics; Journal Volume: 43; Journal Issue: 6; Other Information: (c) 2016 American Association of Physicists in Medicine; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 61 RADIATION PROTECTION AND DOSIMETRY; BEAMS; BONE JOINTS; FARMS; IN VIVO; IONIZATION CHAMBERS; IONS; LINEAR ACCELERATORS; LUMINESCENCE; PATIENTS; QUANTUM DOTS; WHOLE-BODY IRRADIATION

Citation Formats

Kaur, H, Kumar, S, Sarkar, B, Ganesh, T, Giri, U, Jassal, K, Rathinamuthu, S, Gulia, G, Gopal, V, Mohanti, B, and Munshi, A. SU-F-T-327: Total Body Irradiation In-Vivo Dose Measurements Using Optically Stimulated Luminescence (OSL) NanoDots and Farmer Type Ion Chamber. United States: N. p., 2016. Web. doi:10.1118/1.4956512.
Kaur, H, Kumar, S, Sarkar, B, Ganesh, T, Giri, U, Jassal, K, Rathinamuthu, S, Gulia, G, Gopal, V, Mohanti, B, & Munshi, A. SU-F-T-327: Total Body Irradiation In-Vivo Dose Measurements Using Optically Stimulated Luminescence (OSL) NanoDots and Farmer Type Ion Chamber. United States. doi:10.1118/1.4956512.
Kaur, H, Kumar, S, Sarkar, B, Ganesh, T, Giri, U, Jassal, K, Rathinamuthu, S, Gulia, G, Gopal, V, Mohanti, B, and Munshi, A. 2016. "SU-F-T-327: Total Body Irradiation In-Vivo Dose Measurements Using Optically Stimulated Luminescence (OSL) NanoDots and Farmer Type Ion Chamber". United States. doi:10.1118/1.4956512.
@article{osti_22648933,
title = {SU-F-T-327: Total Body Irradiation In-Vivo Dose Measurements Using Optically Stimulated Luminescence (OSL) NanoDots and Farmer Type Ion Chamber},
author = {Kaur, H and Kumar, S and Sarkar, B and Ganesh, T and Giri, U and Jassal, K and Rathinamuthu, S and Gulia, G and Gopal, V and Mohanti, B and Munshi, A},
abstractNote = {Purpose: This study was performed to analyze the agreement between optically stimulated luminescence (OSL) nanoDots measured doses and 0.6 cc Farmer type ionization chamber measured doses during total body irradiation (TBI). Methods: In-vivo dose measurements using OSL nanoDots and Farmer chamber were done in a total of twelve patients who received TBI at our center by bilateral parallel-opposed beams technique. In this technique, the patient is kept inside the TBI box which is filled with rice bags and irradiated using two bilateral parallel opposed beams of 40×40 cm{sup 2} size with 45° collimator rotation at an SSD of 333.5 cm in an Elekta Synergy linear accelerator. All patients received a dose of 2 Gy in single fraction as conditioning regimen. The beams were equally weighted at the midplane of the box. The nanoDots were placed over forehead, right and left neck, right and left lung, umbilicus, right and left abdomen, medial part of thigh, knee and toe. A 0.6 cc Farmer chamber was placed in between the thighs of the patient. Measured doses are reported along with the statistical comparisons using paired sample t-test. Results: For the above sites the mean doses were 212.2±21.1, 218.2±7.6, 218.7±9.3, 215.6±9.5, 217.5±11.5, 214.5±7.7, 218.3±6.8, 221.5±15, 229.1±11.0, 220.5±7.7 and 223.3±5.1 cGy respectively. For all OSL measurements the mean dose was 218.6±11.8 cGy. Farmer chamber measurements yielded a mean dose of 208.8±15.6 cGy. Statistical analysis revealed that there was no significant difference between OSL measured doses in forehead, right and left neck, right and left lung, umbilicus, right and left abdomen and toe and Farmer chamber measured doses (0.72≤p≤0.06). However the mean OSL doses at thigh and knee were statistically different (p<0.05) from the Farmer chamber measurements. Conclusion: OSL measurements were found to be in agreement with Farmer type ionization chamber measurements in in-vivo dosimetry of TBI.},
doi = {10.1118/1.4956512},
journal = {Medical Physics},
number = 6,
volume = 43,
place = {United States},
year = 2016,
month = 6
}
  • Purpose: This study was designed to evaluate the performance of optically stimulated Luminescence (OSL) nanoDots as in-vivo dosimeter. For the measurements of surface doses as well as scattered plus leakage doses, nanoDots were used during the setup verification as well as during the treatment delivery. Methods: For a total seven patients undergoing radiotherapy by volumetric modulated arc therapy, surface doses from image guidance and scattered plus leakage doses from treatment delivery were measured. Two sets of calibration curves were generated – one for therapy and another for imaging. Two different nanoDots were used for imaging and therapy doses. Imaging nanoDotsmore » were placed at the isocenter only at the time of CBCT and therapy nanoDots were placed at 25 cm away from the isocenter (either in cranial or in caudal direction) only at the time of treatment delivery. During the entire course, nanoDots were placed at the same measurement points. NanoDots were read after 15 minutes of their exposure. For the next fraction, nanoDots were corrected for the residual doses from the previous fractions. Results: Measured surface doses during imaging were 0.14±0.32 cGy, 0.11±0.04 cGy, 0.12±0.53 cGy, 0.04±0.02 cGy, 0.13±0.23 cGy, 0.11±0.43 cGy, 0.10±0.04 cGy with overall mean dose of 0.08±0.1 cGy. Measured doses during treatment delivery, indicative of scattered and leakage dose, were 0.84±0.43 cGy, 1.3±0.4 cGy, 1.4±0.4 cGy, 0.18±0.48 cGy, 0.78±0.29 cGy, 0.27±0.08 cGy, 0.78±0.07 cGy with overall mean dose of 0.61±1.3 cGy. Conclusion: This dosimeter can be used as supplementary unit to verify the doses. No change in the prescription is recommended based on nanoDots measurement. This study is on-going therefore we are presenting only mere number of patients. A large volume data will be presented after completion of the study with proper statistical analysis.« less
  • Purpose: To evaluate the feasibility of using optically stimulated luminescence dosimeters (OSLDs) for in-vivo dosimetry of patients undergoing Total Body and Total Marrow Irradiations (TBI and TMI). Methods: TBI treatments of 12 Gy were delivered in 6 BID fractions with the patient on a moving couch under a static 10 MV beam (Synergy, Elekta). TMI treatments of 18 Gy in 9 BID fractions were planned and delivered using a 6 MV TomoTherapy unit (Accuray). To provide a uniform dose to the entire patient length, the treatment was split into 2 adjacent fields junctioned in the thigh region. Our standard clinicalmore » practice involves in vivo dosimetry with MOSFETs for each TBI fraction and TLDs for at least one fraction of the TMI treatment for dose verification. In this study we also used OSLDs. Individual calibration coefficients were obtained for the OSLDs based on irradiations in a solid water phantom to the dose of 50 cGy from Elekta Synergy 10 MV (TBI) and 6 MV (TMI) beams. Calibration coefficients were calculated based on the OSLDs readings taken 2 hrs post-irradiation. For in vivo dosimetry OSLDs were placed alongside MOSFETs for TBI patients and in approximately the same locations as the TLDs for TMI patients. OSLDs were read 2 hours post treatment and compared to the MOSFET and TLD results. Results: OSLD measured doses agreed within 5% with MOSFET and TLD results, with the exception of the junction region in the TMI patient due to very high dose gradient and difficulty of precise and reproducible detector placement. Conclusion: OSLDs are useful for in vivo dosimetry of TBI and TMI patients. The quick post-treatment readout is an advantage over TLDs, allowing the results to be obtained between BID fractions, while wireless detectors are advantageous over MOSFETs for treatments involving a moving couch.« less
  • Purpose: A new readout technology based on pulsed optically stimulating luminescence is introduced (microSTARii, Landauer, Inc, Glenwood, IL60425). This investigation searches for approaches that maximizes the dosimetry accuracy in clinical applications. Methods: The sensitivity of each optically stimulated luminescence dosimeter (OSLD) was initially characterized by exposing it to a given radiation beam. After readout, the luminescence signal stored in the OSLD was erased by exposing its sensing area to a 21W white LED light for 24 hours. A set of OSLDs with consistent sensitivities was selected to calibrate the dose reader. Higher order nonlinear curves were also derived from themore » calibration readings. OSLDs with cumulative doses below 15 Gy were reused. Before an in-vivo dosimetry, the OSLD luminescence signal was erased with the white LED light. Results: For a set of 68 manufacturer-screened OSLDs, the measured sensitivities vary in a range of 17.3%. A sub-set of the OSLDs with sensitivities within ±1% was selected for the reader calibration. Three OSLDs in a group were exposed to a given radiation. Nine groups were exposed to radiation doses ranging from 0 to 13 Gy. Additional verifications demonstrated that the reader uncertainty is about 3%. With an external calibration function derived by fitting the OSLD readings to a 3rd-order polynomial, the dosimetry uncertainty dropped to 0.5%. The dose-luminescence response curves of individual OSLDs were characterized. All curves converge within 1% after the sensitivity correction. With all uncertainties considered, the systematic uncertainty is about 2%. Additional tests emulating in-vivo dosimetry by exposing the OSLDs under different radiation sources confirmed the claim. Conclusion: The sensitivity of individual OSLD should be characterized initially. A 3rd-order polynomial function is a more accurate representation of the dose-luminescence response curve. The dosimetry uncertainty specified by the manufacturer is 4%. Following the proposed approach, it can be controlled to 2%.« less
  • Purpose: To establish patient surface dose dosimetry for scanning proton beam therapy (SPBT) for breast cancer using optically stimulated luminescence dosimeters (OSLD). Methods: OSLDs were calibrated with SPB under the similar conditions as the treatments for breast cancer. A range shifter (RS) of 5 cm water equivalent thickness (WET) was used. The air gap from the surface of the range shifter to the surface of the phantom was 15 cm. A uniform planar dose generated by nominal energy of 118 MeV was delivered. The range of 118 MeV proton beam after the 5cm RS is approximately 5 cm in water,more » which is the common range for breast treatments. The OSLDs were placed on the surface of high density polyethylene slabs, and a bolus of 1.06 cm WET was used for buildup. A variety of dose levels in the range of 0.5 to 8 Gy were delivered. Under the same condition, an ADCL calibrated parallel plate (PP) chamber was used to measure the reference dose. The correlation between the output signals of OSLDs and the reference doses was established. The calibration of OSLD was verified against the PP chamber measurements for two SPBT breast plans calculated for two patients. Results: the least squares fitting for the OSLD calibration curve was a polynomial function to the order of 2 in the range of 0.5 to 8 Gy (RBE). The differences between the dose measured with OSLDs and PP chamber were within 3% for the two breast proton plans. Conclusion: the calibrated OSLDs under the similar conditions as the treatments can be used for patient surface dose measurements.« less
  • Purpose: To show the feasibility of clinical implementation of OSLDs for high dose-rate (HDR) in vivo dosimetry for gynecological and breast patients. To discuss how the OSLDs were characterized for an Ir-192 source, taking into account low gamma energy and high dose gradients. To describe differences caused by the dose calculation formalism of treatment planning systems.Methods: OSLD irradiations were made using the GammaMedplus iX Ir-192 HDR, Varian Medical Systems, Milpitas, CA. BrachyVision versions 8.9 and 10.0, Varian Medical Systems, Milpitas, CA, were used for calculations. Version 8.9 used the TG-43 algorithm and version 10.0 used the Acuros algorithm. The OSLDsmore » (InLight Nanodots) were characterized for Ir-192. Various phantoms were created to assess calculated and measured doses and the angular dependence and self-absorption of the Nanodots. Following successful phantom measurements, patient measurements for gynecological patients and breast cancer patients were made and compared to calculated doses.Results: The OSLD sensitivity to Ir-192 compared to 6 MV is between 1.10 and 1.25, is unique to each detector, and changes with accumulated dose. The measured doses were compared to those predicted by the treatment planning system and found to be in agreement for the gynecological patients to within measurement uncertainty. The range of differences between the measured and Acuros calculated doses was -10%-14%. For the breast patients, there was a discrepancy of -4.4% to +6.5% between the measured and calculated doses at the skin surface when the Acuros algorithm was used. These differences were within experimental uncertainty due to (random) error in the location of the detector with respect to the treatment catheter.Conclusions: OSLDs can be successfully used for HDR in vivo dosimetry. However, for the measurements to be meaningful one must account for the angular dependence, volume-averaging, and the greater sensitivity to Ir-192 gamma rays than to 6 MV x-rays if 6 MV x-rays were used for OSLD calibration. The limitations of the treatment planning algorithm must be understood, especially for surface dose measurements. Use of in vivo dosimetry for HDR brachytherapy treatments is feasible and has the potential to detect and prevent gross errors. In vivo HDR brachytherapy should be included as part of the QA for a HDR brachytherapy program.« less